Synthetic Biology Market – Engineering Life for Healthcare, Agriculture, and Sustainable Manufacturing

The synthetic biology market is a rapidly growing segment of the biotechnology industry, providing tools and technologies for designing and constructing new biological parts, devices, and systems, or re-designing existing natural biological systems for useful purposes. With applications spanning healthcare, industrial biotechnology, agriculture, environmental solutions, and food and nutrition, synthetic biology is transforming how we produce medicines, materials, and sustainable alternatives to petrochemical products.

The market was valued at USD 18.63 billion in 2024, about USD 23.46 billion in 2025, and is projected to reach roughly USD 234.78 billion by 2035, growing at a CAGR of approximately 25.9%. Growth is driven by declining DNA synthesis and sequencing costs, AI-guided protein and pathway design, government bio-economy funding mandates, corporate net-zero and ESG commitments, cell and gene therapy pipeline expansion, precision fermentation for alternative proteins, and automated biofoundry infrastructure build-out.

By application, healthcare holds the largest share (57.1%), reflecting its critical role in cell and gene therapies, mRNA platforms, and engineered diagnostics. Chemicals (including biofuels) is the second-largest segment, while food and agriculture is the fastest-growing application, propelled by regulatory approvals for precision fermentation-derived dairy proteins and gene-edited crops.

By technology, genome engineering leads (35.4%), driven by CRISPR-Cas9 therapeutic approvals and agricultural gene editing. Bioinformatics and CAD tools are the fastest-growing technology segment, as machine-learning models increasingly guide the design of biological circuits, metabolic pathways, and protein structures.

By product type, core products (synthetic genes, oligonucleotides, synthetic cells, and chassis organisms) dominate with 51.2% market share, while enabling products (DNA synthesis platforms, genome-editing kits, and bioinformatics software) represent the fastest-growing product category at 18.1% CAGR.

By end-use industry, industrial biotech companies hold the largest share (41.4%), purchasing synthetic DNA, engineered enzymes, and bio-process optimization services at scale. Pharmaceutical and biotechnology companies constitute the second-largest buyer group, while defense and government labs are the fastest-growing end-user category.

Regionally, North America leads with 46.0% market share, supported by venture-backed biofoundries and federal biomanufacturing mandates. Europe follows with 24.1%, while Asia-Pacific is the fastest-growing region at 19.7% CAGR, driven by government bio-economy roadmaps and gene-therapy manufacturing.

Key players include Thermo Fisher Scientific, Ginkgo Bioworks, Twist Bioscience, Agilent Technologies, Merck KGaA, GenScript Biotech, Codexis, and Novonesis (formerly Novozymes). Strategies focus on developing innovative synthetic biology platforms, integrating AI and automation, and forming strategic partnerships to expand market reach.

Read more: Synthetic Biology Market Size, Share & Global Trends 2035

People Also Ask

Q1. What is synthetic biology and why is it important?
Synthetic biology is the design and construction of new biological parts, devices, and systems, or re-designing existing natural biological systems for useful purposes, enabling innovations in healthcare, agriculture, sustainable manufacturing, and environmental solutions.

Q2. Which region leads the synthetic biology market?
North America leads due to venture-backed biofoundries and federal biomanufacturing mandates, while Asia-Pacific is emerging rapidly, driven by government bio-economy roadmaps and gene-therapy manufacturing.

Tags: synthetic biology, gene editing, CRISPR, biofoundry, precision fermentation, biomanufacturing